



## CLINICAL INSIGHTS

*BLUE CROSS Division of Blue Cross Laboratories*

**EXTACEF-100 DT/ EXTACEF-200 Tablets**

**Issue XI, No.31, 2025**

### **Clinical Effectiveness and Safety of Cefixime in Managing Typhoid Fever in Indian Population: A Real-world Evidence Study**

*Parikh K et.al; Annals of Medicine and Medical Sciences; Vol.4; 2025*

- The purpose of this study was to evaluate the effectiveness and safety of cefixime for managing typhoid fever among Indian patients.
- Multicenter, single-arm retrospective study assessed the data of 6247 patients from the medical records, who had received cefixime for typhoid during the period Jan 2023 to Apr 2024. At end-of-therapy ( $7\pm2$  days) and follow-up period ( $14\pm2$  days), assessment included clinical outcome, persisting symptoms, laboratory tests, and adverse event incidences.
- A majority of patients demonstrated clinical cure (96.68%) at  $7\pm2$  days, which increased to 99.35% at  $14\pm2$  days. Incidence of adverse events was rare, with 6 (0.09%) and 4 (0.06%) documented cases at  $7\pm2$  days and  $14\pm2$  days, respectively. The average duration of cefixime therapy was 8.21 (3.68) days, with a mean duration of hospital stay of 7.60 (3.84) days.
- Cefixime demonstrated high effectiveness in improving signs and symptoms of typhoid fever, with over 99% of the patients showing clinical cure at the post-therapy follow-up assessment.

**Cefixime demonstrated high effectiveness and a favorable safety profile among Indian patients with typhoid fever.**

